The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) hit a new 52-week low and has $42.48 target or 8.00% below today’s $46.17 share price. The 7 months bearish chart indicates high risk for the $46.16 billion company. The 1-year low was reported on Sep, 30 by Barchart.com. If the $42.48 price target is reached, the company will be worth $3.69B less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 9.08 million shares traded hands or 50.33% up from the average. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has declined 18.76% since February 26, 2016 and is downtrending. It has underperformed by 29.19% the S&P500.
Analysts await Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) to report earnings on November, 3. They expect $1.30 EPS, down 3.70% or $0.05 from last year’s $1.35 per share. TEVA’s profit will be $1.30B for 8.88 P/E if the $1.30 EPS becomes a reality. After $1.25 actual EPS reported by Teva Pharmaceutical Industries Ltd (ADR) for the previous quarter, Wall Street now forecasts 4.00% EPS growth.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) Ratings Coverage
Out of 19 analysts covering Teva Pharma (NYSE:TEVA), 15 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 79% are positive. Teva Pharma has been the topic of 28 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has “Buy” rating given on Monday, July 18 by HSBC. The rating was initiated by Wells Fargo on Friday, February 19 with “Outperform”. The firm earned “Buy” rating on Tuesday, May 10 by Mizuho. Morgan Stanley reinitiated Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) on Wednesday, July 29 with “Overweight” rating. Mizuho initiated Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) rating on Monday, December 7. Mizuho has “Buy” rating and $79 price target. On Thursday, July 14 the stock rating was maintained by Oppenheimer with “Outperform”. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has “Positive” rating given on Thursday, September 29 by OTR Global. The company was maintained on Monday, July 27 by Maxim Group. On Monday, July 27 the stock rating was maintained by Standpoint Research with “Buy”. The rating was reinitiated by JP Morgan with “Overweight” on Monday, August 3.
According to Zacks Investment Research, “TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended and immediate release tablets and capsules, creams, ointments, solutions, and suspensions. Key therapeutic areas are the analgesic, anti-infective, cardiovascular, CNS, dermatological and anti-inflammatory categories.”
TEVA Company Profile
Teva Pharmaceutical Industries Limited, incorporated on February 13, 1944, is a global pharmaceutical company. The Firm is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Firm operates through two divisions: Generic medicines and Specialty medicines. The Firm has a global portfolio of approximately 1,000 molecules.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.